Skip to main
CANF

CANF Stock Forecast & Price Target

CANF Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Can Fite Biopharma Ltd is positioned for strong financial growth, with projections indicating risk-adjusted global sales reaching approximately $19.7 million in 2031 for its drug candidate Namodenoson, projected to enter the market in early 2028. Additionally, from 2027 to 2031, risk-adjusted product revenues are expected to rise significantly from around $3 million to $126 million, showcasing the potential for substantial revenue growth as the company advances its pipeline. The recent clinical successes and ongoing studies of its drug candidates, especially with the favorable outcomes for piclidenoson and the compelling case of Namodenoson's impact on advanced liver cancer, further enhance the overall positive outlook for Can Fite’s market position.

Bears say

Can Fite Biopharma Ltd has encountered significant challenges that negatively impact its financial outlook, including the potential inability to successfully commercialize its products and lower-than-expected market penetration, which could hinder revenue projections. The company recorded a net loss of $4.9 million in the first half of 2025 and anticipates a total net loss of $10 million for the year, leading to an adjustment in its financial model which incorporates potential dilution and reduces the price target from $11.0 to $4.0. Additionally, delays in obtaining regulatory approvals, patient enrollment in clinical trials, and management's ability to protect intellectual property pose further risks to Can-Fite's commercial viability and growth prospects.

CANF has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Can-Fite BioPharma Ltd. (CANF) Forecast

Analysts have given CANF a Strong Buy based on their latest research and market trends.

According to 2 analysts, CANF has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Can-Fite BioPharma Ltd. (CANF)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.